APONTIS PHARMA Reports Positive Start to FY 2024 with Increase in Single Pill Revenue

APONTIS PHARMA AG announced a strong start to the financial year 2024, reporting substantial growth in its core business of Single Pill combinations and a return to profitability in the first quarter. The pharmaceutical company recorded an increase in Single Pill revenues to EUR 8.8 million, up from EUR 6.6 million in the same period last year, which constitutes a 35% rise. This growth was notably influenced by a competitor's temporary supply chain issues.

Despite a decline in its cooperation business, down to EUR 0.9 million from EUR 2.7 million in Q1 2023, the company's total sales remained steady at EUR 10.0 million. Additionally, APONTIS PHARMA achieved a positive net result of EUR 0.4 million, a significant improvement from the EUR -1.5 million loss reported in the first quarter of 2023. The company attributes these results to a reduced cost base and successful restructuring efforts.

EBITDA also showed improvement, reaching EUR 1.0 million compared to a loss of EUR -1.5 million in the previous year, reflecting enhanced operational efficiency. The financial outlook for 2024 has been upgraded following a new distribution and marketing agreement with Novartis for two asthma medications, underscoring a strategic shift towards growth and increased market presence.